NCT01593397View on ClinicalTrials.gov

Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

PHASE1CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions

Obesity

Interventions

DRUG

Propofol and Fentanyl administration

Propofol will be administered to all patients via infusion at a dose of 2 mg/kg lean body weight/minute. The infusion will stop once loss of consciousness is reached. Fentanyl will be administered via target controlled infusion to achieve a plasma concentration of 2 ng/ml.

Trial Locations (1)

94305

Stanford University School of Medicine, Department of Anesthesia, Stanford

All Listed Sponsors

collaborator

National Institute of General Medical Sciences (NIGMS)

NIH

lead

Stanford University

OTHER

NCT01593397 - Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity | Biotech Hunter | Biotech Hunter